Last reviewed · How we verify
Esketamine DPI - medium dose
At a glance
| Generic name | Esketamine DPI - medium dose |
|---|---|
| Sponsor | Celon Pharma SA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression (PHASE2)
- Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression (PHASE2)
- Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |